FluBlok®
FluBlok® is Protein Sciences' seasonal influenza vaccine candidate.
The company has conducted Phase III clinical studies for FluBlok. At this time a Biologics License Application (BLA) for commercialization of FluBlok is under review at the FDA.
FluBlok is comprised of purified recombinant hemagglutinin antigens (active ingredient) and is formulated to contain 3X the active component as compared to TIV.
Over 90% of influenza-related deaths occur in people over the age of 65. Currently available vaccines have a limited ability to protect the elderly, the age group most at risk for influenza. In clinical trials to date, FluBlok has demonstrated that a significantly higher percentage of elderly subjects developed antibody titers that are considered to be protective compared to licensed vaccine.
FluBlok Advantages:
- Higher antigen content
- Better immunogenicity for the elderly
- No preservatives and no adjuvants (i.e. no thimerisol)
- No egg proteins present
- No live influenza viruses used in productio
Posts
